BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7833476)

  • 21. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
    Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.
    Bray B; Lane DA; Freyssinet JM; Pejler G; Lindahl U
    Biochem J; 1989 Aug; 262(1):225-32. PubMed ID: 2818566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of heparin cofactor II by heparin and dermatan sulfate.
    Tollefsen DM
    Nouv Rev Fr Hematol (1978); 1984; 26(4):233-7. PubMed ID: 6548014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II.
    Yamagishi R; Koide T; Sakuragawa N
    FEBS Lett; 1987 Dec; 225(1-2):109-12. PubMed ID: 3691797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermatan sulfate and heparin can be fractionated by affinity for heparin cofactor II.
    Griffith MJ; Marbet GA
    Biochem Biophys Res Commun; 1983 Apr; 112(2):663-70. PubMed ID: 6687802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly sulfated dermatan sulfates from Ascidians. Structure versus anticoagulant activity of these glycosaminoglycans.
    Pavão MS; Aiello KR; Werneck CC; Silva LC; Valente AP; Mulloy B; Colwell NS; Tollefsen DM; Mourão PA
    J Biol Chem; 1998 Oct; 273(43):27848-57. PubMed ID: 9774395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin cofactor II-dependent antithrombin activity of calcium spirulan.
    Hayakawa Y; Hayashi T; Hayashi K; Hayashi T; Ozawa T; Niiya K; Sakuragawa N
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):554-60. PubMed ID: 8874866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inhibition of thrombin and chymotrypsin by heparin-cofactor II.
    Struss D; Storck J; Zimmermann RE
    Thromb Res; 1992 Oct; 68(1):45-56. PubMed ID: 1333106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A; Dawes J
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives.
    Maaroufi RM; Tapon-Bretaudiere J; Mardiguian J; Sternberg C; Dautzenberg MD; Fischer AM
    Thromb Res; 1990 Aug; 59(4):749-58. PubMed ID: 2080493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin.
    Tykesson E; Maccarana M; Thorsson H; Liu J; Malmström A; Ellervik U; Westergren-Thorsson G
    Glycobiology; 2019 Jun; 29(6):446-451. PubMed ID: 30869126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of heparin cofactor II function by S protein (vitronectin) and formation of a ternary S protein-thrombin-heparin cofactor II complex.
    Preissner KT; Sié P
    Thromb Haemost; 1988 Dec; 60(3):399-406. PubMed ID: 2976993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells.
    McGuire EA; Tollefsen DM
    J Biol Chem; 1987 Jan; 262(1):169-75. PubMed ID: 3793724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of thrombin inhibition by heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative.
    Maaroufi RM; Jozefowicz M; Tapon-Bretaudière J; Jozefonvicz J; Fischer AM
    Biomaterials; 1997 Feb; 18(4):359-66. PubMed ID: 9068899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of heparin cofactor II anticoagulant activity.
    Bauman SJ; Church FC
    J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
    Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
    J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of lysine 173 in heparin binding to heparin cofactor II.
    Whinna HC; Blinder MA; Szewczyk M; Tollefsen DM; Church FC
    J Biol Chem; 1991 May; 266(13):8129-35. PubMed ID: 1902471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.